Edison Oncology Reports Promising Interim Data from Ongoing Orotecan® Clinical Trial for Recurrent Pediatric Cancers Apr 08, 2024 10:28am EDT
Edison Oncology Announces Presentation of Two Scientific Posters at AACR Annual Meeting Apr 20, 2023 10:09am EDT
Edison Oncology Announces Treatment of First Patient in Orotecan® (irinotecan HCI oral solution) Phase I/IIa Clinical Trial for Patients with Recurrent Pediatric Solid Tumors Feb 17, 2022 9:00am EST
Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial Sep 30, 2021 7:10am EDT
Edison Oncology Partners DNA-damage Response Inhibitor Program with Rakovina Therapeutics Apr 01, 2021 2:30pm EDT
Edison Oncology to Participate in the 10th Annual SVB Leerink Global Healthcare Conference Feb 16, 2021 9:00am EST
Apollomics, Inc. and Edison Oncology Announce Licensing Agreement for Novel Protein Tyrosine Kinase Inhibitor Targeting Solid Tumors Feb 09, 2021 7:10pm EST
